Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Stock Information for Marker Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.